• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.肠道移植后巨细胞病毒病发生的发病率及相关危险因素。
Transplantation. 1995 Apr 15;59(7):1010-4. doi: 10.1097/00007890-199504150-00016.
2
Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.肠道和多脏器移植受者中的耐巨细胞病毒情况
Transpl Infect Dis. 2016 Apr;18(2):202-9. doi: 10.1111/tid.12507.
3
Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients.小肠移植受者巨细胞病毒病的发病率、危险因素及预后
Pediatr Transplant. 2012 May;16(3):294-301. doi: 10.1111/j.1399-3046.2011.01628.x. Epub 2011 Dec 29.
4
Early and late virological monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients.小肠/多脏器移植受者巨细胞病毒、EB病毒和人疱疹病毒6型感染的早期和晚期病毒学监测
Transplant Proc. 2010 Jan-Feb;42(1):74-8. doi: 10.1016/j.transproceed.2009.12.032.
5
CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.肝移植后巨细胞病毒肝炎:发病率、临床病程及长期随访
Liver Transpl. 2002 Dec;8(12):1138-46. doi: 10.1053/jlts.2002.36732.
6
Cytomegalovirus infection after liver transplantation: current concepts and challenges.肝移植后的巨细胞病毒感染:当前概念与挑战
World J Gastroenterol. 2008 Aug 21;14(31):4849-60. doi: 10.3748/wjg.14.4849.
7
Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.接受抗病毒预防的供体血清学阳性/受体血清学阴性肾移植受者发生迟发性巨细胞病毒病的危险因素。
Transpl Infect Dis. 2011 Jun;13(3):244-9. doi: 10.1111/j.1399-3062.2011.00624.x. Epub 2011 Mar 17.
8
Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.肝移植和肠移植中使用更昔洛韦和巨细胞病毒免疫球蛋白进行巨细胞病毒预防
Transpl Infect Dis. 2001;3 Suppl 2:35-9. doi: 10.1034/j.1399-3062.2001.00007.x.
9
Cytomegalovirus infection after intestinal transplantation in children.儿童肠道移植后的巨细胞病毒感染
Clin Infect Dis. 1997 Nov;25(5):1078-83. doi: 10.1086/516113.
10
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.抢先治疗与抗病毒预防对供体血清阳性受者血清阴性肝移植患者巨细胞病毒病的影响:一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138.

引用本文的文献

1
Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.病毒载量在实体器官移植后巨细胞病毒感染管理中的临床应用。
Clin Microbiol Rev. 2013 Oct;26(4):703-27. doi: 10.1128/CMR.00015-13.
2
Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients.儿童移植受者中针对巨细胞病毒的细胞介导免疫反应动力学
Pediatr Transplant. 2012 Feb;16(1):18-28. doi: 10.1111/j.1399-3046.2011.01531.x. Epub 2011 Jul 18.
3
Calprotectin: a novel noninvasive marker for intestinal allograft monitoring.钙卫蛋白:一种用于肠道同种异体移植监测的新型非侵入性标志物。
Ann Surg. 2007 Aug;246(2):311-5. doi: 10.1097/SLA.0b013e3180f61af4.
4
Small intestine transplantation today.今日的小肠移植
Langenbecks Arch Surg. 2007 May;392(3):227-38. doi: 10.1007/s00423-006-0134-5. Epub 2007 Jan 25.
5
Zoom endoscopic monitoring of small bowel allograft rejection.小肠同种异体移植排斥反应的变焦内镜监测
Surg Endosc. 2006 May;20(5):773-82. doi: 10.1007/s00464-005-0331-2. Epub 2006 Mar 16.
6
Viral prophylaxis in organ transplant patients.器官移植患者的病毒预防
Drugs. 2004;64(24):2763-92. doi: 10.2165/00003495-200464240-00004.
7
Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation.口服缬更昔洛韦与静脉注射更昔洛韦在一名接受小肠移植的成年患者中预防巨细胞病毒疾病的药代动力学。
Antimicrob Agents Chemother. 2004 Jul;48(7):2782-3. doi: 10.1128/AAC.48.7.2782-2783.2004.
8
The role of intestinal transplantation in the management of intestinal failure.肠道移植在肠道衰竭管理中的作用。
Curr Gastroenterol Rep. 2001 Aug;3(4):334-42. doi: 10.1007/s11894-001-0057-9.
9
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.实体器官移植受者巨细胞病毒感染及疾病的预防和治疗新策略。
Clin Microbiol Rev. 2000 Jan;13(1):83-121, table of contents. doi: 10.1128/CMR.13.1.83.
10
Current status of intestinal transplantation in children.儿童肠道移植的现状
J Pediatr Surg. 1998 Feb;33(2):243-54. doi: 10.1016/s0022-3468(98)90440-7.

本文引用的文献

1
Technical aspects of intestinal transplantation.肠道移植的技术层面
Surg Technol Int. 1993 Oct;2:165-70.
2
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.全器官移植后的细胞迁移与嵌合现象:移植物接受的基础
Hepatology. 1993 Jun;17(6):1127-52.
3
Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement.在伴有器官受累的播散性人巨细胞病毒(HCMV)感染中可检测到对HCMV易感的循环内皮巨细胞。
J Clin Invest. 1993 Aug;92(2):663-70. doi: 10.1172/JCI116635.
4
Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients.巨细胞病毒感染——排斥反应的一个病因?对242例肾移植患者的前瞻性研究。
Transplantation. 1993 Apr;55(4):851-7. doi: 10.1097/00007890-199304000-00032.
5
Murine liver allograft transplantation: tolerance and donor cell chimerism.小鼠肝脏同种异体移植:耐受性与供体细胞嵌合现象
Hepatology. 1994 Apr;19(4):916-24. doi: 10.1002/hep.1840190418.
6
Early infectious complications of liver-intestinal transplantation in children: preliminary analysis.儿童肝肠移植的早期感染性并发症:初步分析
Transplant Proc. 1994 Jun;26(3):1420-1.
7
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation.在肾、肝、心脏和胰岛移植中通过骨髓增强供体细胞嵌合现象。
Lancet. 1994 Jul 16;344(8916):151-5. doi: 10.1016/s0140-6736(94)92756-1.
8
Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis.在抗病毒预防期间通过空斑试验和传统细胞培养诊断巨细胞病毒感染
J Clin Microbiol. 1994 Nov;32(11):2655-9. doi: 10.1128/jcm.32.11.2655-2659.1994.
9
Monitoring and treatment of intestinal allograft rejection in humans.人类肠道同种异体移植排斥反应的监测与治疗
Transplant Proc. 1993 Feb;25(1 Pt 2):1202-3.
10
Infectious complications after small bowel transplantation in adults.成人小肠移植后的感染性并发症
Transplant Proc. 1994 Jun;26(3):1682-3.

肠道移植后巨细胞病毒病发生的发病率及相关危险因素。

Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

作者信息

Mañez R, Kusne S, Green M, Abu-Elmagd K, Irish W, Reyes J, Furukawa H, Tzakis A, Fung J J, Todo S

机构信息

Department of Surgery, University of Pittsburgh Transplantation Institute, Pennsylvania 15213, USA.

出版信息

Transplantation. 1995 Apr 15;59(7):1010-4. doi: 10.1097/00007890-199504150-00016.

DOI:10.1097/00007890-199504150-00016
PMID:7709436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3033117/
Abstract

From May 1990 to March 1993, 38 patients (21 adults and 17 children) received 40 allografts that included the small bowel (14 isolated small bowel, 21 small bowel and liver, and 5 multivisceral transplantations). Fifteen patients (39%) had 26 episodes of CMV disease: 7 with one episode, 6 with two, and 1 each with three and four. CMV enteritis accounted for 21 (81%) of the episodes, hepatitis and pneumonitis for 2 each, and a viral syndrome for 1. Cox's proportional hazards univariate and multivariate analyses showed that significant first-episode risk factors were: CMV seropositive donors for negative recipients (relative risk [RR], 3.86; P = 0.02), the average daily plasma trough level of tacrolimus (RR, 2.15; P = 0.04), and total amount of steroid boluses (RR, 2.90; P = 0.02). CMV disease recurrence factors were: CMV seronegative recipients (RR, 8.60; P = 0.02) and total amount of steroid bolus pulses (RR, 12.39; P = 0.004). Because long courses of ganciclovir prophylaxis could not prevent the development of CMV disease, avoidance of CMV seropositive grafts in seronegative recipients and new strategies to prevent heavy immunosuppression without the penalty of rejection will be necessary to ameliorate this problem in intestinal transplant recipients.

摘要

1990年5月至1993年3月,38例患者(21例成人和17例儿童)接受了40例同种异体移植,包括小肠(14例孤立小肠、21例小肠和肝脏以及5例多脏器移植)。15例患者(39%)发生了26次巨细胞病毒(CMV)疾病发作:7例发作1次,6例发作2次,1例发作3次,1例发作4次。CMV肠炎占发作次数的21次(81%),肝炎和肺炎各占2次,还有1次为病毒综合征。Cox比例风险单因素和多因素分析显示,首次发作的显著危险因素为:CMV血清学阳性供体对血清学阴性受体(相对风险[RR],3.86;P = 0.02)、他克莫司的平均每日血浆谷浓度(RR,2.15;P = 0.04)以及类固醇冲击总量(RR,2.90;P = 0.02)。CMV疾病复发因素为:CMV血清学阴性受体(RR,8.60;P = 0.02)和类固醇冲击脉冲总量(RR,12.39;P = 0.004)。由于长期使用更昔洛韦预防不能预防CMV疾病的发生,对于肠道移植受者,避免血清学阴性受体接受CMV血清学阳性移植物以及采用新策略预防严重免疫抑制而不增加排斥反应风险对于改善这一问题将是必要的。